| Schedule of Consolidated Statements of Operations |
Additional disaggregated significant
segment expenses on a functional basis, that are not separately presented on the Company’s consolidated statements of operations,
regularly reviewed by the Company’s CODM, include salaries and clinical trials expenses and presented below.
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
| Salaries and related expenses, other than share-based compensation |
|
|
1,932 |
|
|
|
3,521 |
|
|
|
3,909 |
|
|
|
5,900 |
|
| Clinical trials |
|
|
3,424 |
|
|
|
3,034 |
|
|
|
7,049 |
|
|
|
4,720 |
|
| Stock based compensation |
|
|
696 |
|
|
|
77 |
|
|
|
1,355 |
|
|
|
254 |
|
| Depreciation expenses |
|
|
292 |
|
|
|
331 |
|
|
|
528 |
|
|
|
560 |
|
| Other segment items (*) |
|
|
1,089 |
|
|
|
2,762 |
|
|
|
2,348 |
|
|
|
5,076 |
|
| Total Operating expenses |
|
|
7,433 |
|
|
|
9,725 |
|
|
|
15,189 |
|
|
|
16,510 |
|
| (*) | Other segment items include all remaining costs necessary to operate the Company’s business, which primarily include external professional services, rent, insurance and other administrative expenses, and are presented net of grants received. |
|
| Schedule of Consolidated Balance Sheets |
The Company’s Property and equipment,
as well as the Company’s operating lease right-of-use assets recognized on the consolidated balance sheets were located as follows:
| |
|
As of
June 30, |
|
|
As of
December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Israel |
|
|
5,516 |
|
|
|
6,090 |
|
| United States |
|
|
3,688 |
|
|
|
4,412 |
|
| Total |
|
|
9,204 |
|
|
|
10,502 |
|
|